Navigation Links
New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer'
Date:12/16/2009

CLEVELAND -- December 16, 2009 -- Every year in the United States, 160,000 cases of colorectal cancer are diagnosed, and 57,000 patients die of the disease, making it the second leading cause of death from cancer among adults, after lung cancer.

As researchers and clinicians fervently look for causes and cures for colorectal cancer -- simultaneously generating thousands of studies producing more and more promising results Dr. Sanford Markowitz, professor and researcher of cancer and genetics at Case Western Reserve University School of Medicine and oncologist at the Case Comprehensive Cancer Center at University Hospitals Case Medical Center, today published his forward-looking view of the "Molecular Basis of Colorectal Cancer" in the Dec. 17, 2009 issue of the New England Journal of Medicine, with co-author, Dr. Monica Bertagnolli, from the Brigham and Women's Hospital, Harvard Medical School.

"Today's challenges are to understand the molecular basis of individual susceptibility to colorectal cancer and to determine factors that initiate the development of the tumor, drive its progression, and determine its responsiveness or resistance to antitumor agents," wrote Dr. Markowitz.

Key advances that the article singled out toward meeting these goals are:

  • Discoveries in DNA sequencing technology have made it possible to sequence the entire genome of a human cancer. Colorectal cancer provided the first example of the power of this technology. Sequencing of 18,000 (nearly all) of the known human genes in 35 colon cancers identified 140 as candidate cancer genes that were mutated in at least two colon cancers and that probably contributed to the cancer phenotype.

  • Biological pathways that are deregulated in colon cancer have been identified, and could now form the basis of new therapeutic agents. Although some high-frequency mutations are attractive targets for drug development, common signaling pathways downstream from these mutations may also be tractable as therapeutic targets.

  • Studies that aid in the understanding of colorectal cancer on a molecular level have provided important tools for genetic testing for high-risk familial forms of the disease, predictive markers for selecting patients for certain classes of drug therapies and molecular diagnostics for the noninvasive detection of early cancers.

  • Recent progress in molecular assays for the early detection of colorectal cancer indicates that understanding the genes and pathways that control the earliest steps of the disease, and individual susceptibility, can contribute to clinical management in the near term. For example, patients whose colon cancers have mutations in either RAS or BRAF genes are known not to benefit from treatment with the anti-colon cancer agent Cetuximab.

  • Moreover, patients with inherited mutations in tumor-suppressor genes, such as APC, MLH1, and MSH2 have a very high risk of colorectal cancer and require early and frequent surveillance for colon cancer and often prophylactic surgery.

  • Last, the development of molecular diagnostics for the early detection of colorectal cancer is emerging as an important translation of colon-cancer genetics into clinical practice. One example is the development of stool DNA tests to detect cancer-associated aberrant DNA methylation as a method for early detection of patients with colorectal cancer or advanced adenomas. Stool DNA testing for colorectal cancer has been added to the cancer-screening guidelines of the American Cancer Society.

Dr. Markowitz and Bertagnolli's concluding observations are optimistic ones that the considerable recent and ongoing advances in our knowledge of the molecular basis of colorectal cancer will continue to result in markedly reducing the burden of this disease.

Dr. Markowitz reports being listed on patents licensed to Exact Sciences and LabCorp and is entitled to receive royalties on sales of products related to methylated vimentin DNA, in accordance with the policies of Case Western Reserve University. No other potential conflict of interest relevant to this article was reported.


'/>"/>

Contact: Christina DeAngelis
cat41@case.edu
216-368-3635
Case Western Reserve University
Source:Eurekalert

Related medicine news :

1. Andrew C. Meyer, Jr. and Robert M. Higgins Named Top 100 New England Super Lawyers
2. New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform
3. FDAs Woodcock Discusses Pain Management and Drug Safety in Nov. 26, 2009 Issue of The New England Journal of Medicine
4. IPC The Hospitalist Company Acquires Two New England Practices
5. Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints
6. Patients More Likely to Die While in ICU in U.S. Than in England
7. Patients in US 5 times more likely to spend last days in ICU than patients in England
8. Detailed Results from RV 144 HIV Vaccine Trial Published Today in The New England Journal of Medicine and Presented at the AIDS Vaccine 2009 Conference Provide Insight for Future Research
9. Vascular Study Group of New England Selects Clinical Data Pathways, Powered by M2S, as Quality Improvement Registry Provider
10. New England Journal of Medicine Also Publishes Mayo Clinic Study of Physicians Beliefs About Health Care Reform
11. Mayo Clinic Offers Perspective on Health Care Reform in New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... PureLife Dental is pleased ... separator supplier for CDA members. As part of the amalgam separator endorsement, all CDA ... saving more than $400 off the retail value. This partnership between PureLife and CDA ...
(Date:6/23/2017)... ... 2017 , ... Ulster University, Magee Campus in Northern Ireland is hosting The ... to present to graduate students exciting new and innovative hope research based on iFred’s ... The Health Improvement Service of the Western Health & Social Care Trust (WHSCT) in ...
(Date:6/23/2017)... ... June 23, 2017 , ... All-Star Insurance, a family managed agency that offers ... Texas, is announcing the launch of a new charity drive to benefit women in ... United States reveal that an estimated 252, 710 new cases of invasive or high ...
(Date:6/22/2017)... ... ... Branches, Inc. has been partnering with The Miami Foundation for over 9 ... focused on providing opportunity to low-income families and breaking the cycle of generational poverty. ... to support its , Climb to College & Career initiative which focuses on postsecondary ...
(Date:6/22/2017)... ... June 22, 2017 , ... Groove Ring is excited ... about their high performance silicon wedding bands and all-purpose rings. Whether you’re an athlete, ... silicone rings designed just for you. , From the rock face to the auto ...
Breaking Medicine News(10 mins):
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
(Date:5/29/2017)... Israel, May 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... technology which enables the functional selection of stem cells, ... for the first quarter ended March 31 st , ... our accomplishments in the first quarter of 2017," said ... quarter, we announced the treatment of the first blood ...
(Date:5/22/2017)... VALLEY COTTAGE, N.Y. , May 22, 2017 ... natural antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of ... in plain English, the results of a clinical ... after one year treatment with Gene-Eden-VIR/Novirin in individuals ... is important to note that there are no ...
Breaking Medicine Technology: